Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

ClinicalTrials.gov ID: NCT01928537

Public ClinicalTrials.gov record NCT01928537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine

Study identification

NCT ID: NCT01928537
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Traws Pharma, Inc.; Industry
Enrollment: 67 participants

Conditions and interventions

Conditions

Interventions

rigosertib sodium Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2013
Primary completion: Jun 28, 2017
Completion: Jun 28, 2017
Last update posted: Jun 29, 2020

2013 – 2017

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Stanford University Cancer Center	Stanford	California	94305	—
Rush University Medical Center	Chicago	Illinois	60612	—
University of Chicago Medicine	Chicago	Illinois	60637	—
University of Kansas Cancer Center and Medical Pavilion	Westwood	Kansas	66205	—
Greenbaum Cancer Center University of Maryland	Baltimore	Maryland	21201	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Mayo Clinic	Rochester	Minnesota	55905	—
Mount Sinai Medical Center	New York	New York	10029	—
Columbia University Medical Center	New York	New York	10032	—
New York Presbyterian Hospital-Weill Cornell Medical College	New York	New York	10065	—
Montefiore Medical Center	The Bronx	New York	10461	—
University of Texas Southwestern Medical Center-Parkland Hospital	Dallas	Texas	75235	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01928537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 29, 2020 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01928537 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →